This company listing is no longer active
0IF Stock Overview
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LogicBio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.87 |
| 52 Week High | €2.84 |
| 52 Week Low | €0.26 |
| Beta | 4.62 |
| 1 Month Change | -10.10% |
| 3 Month Change | 274.00% |
| 1 Year Change | -25.20% |
| 3 Year Change | -76.33% |
| 5 Year Change | n/a |
| Change since IPO | -71.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | -4.9% | -1.5% |
| 1Y | -25.2% | -19.9% | 0.9% |
Return vs Industry: 0IF underperformed the German Biotechs industry which returned 1.4% over the past year.
Return vs Market: 0IF underperformed the German Market which returned -21.6% over the past year.
Price Volatility
| 0IF volatility | |
|---|---|
| 0IF Average Weekly Movement | 208.8% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0IF's share price has been volatile over the past 3 months.
Volatility Over Time: 0IF's weekly volatility has increased from 102% to 209% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 62 | Fred Chereau | www.logicbio.com |
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.
LogicBio Therapeutics, Inc. Fundamentals Summary
| 0IF fundamental statistics | |
|---|---|
| Market cap | €68.23m |
| Earnings (TTM) | -€25.61m |
| Revenue (TTM) | €10.38m |
5.9x
P/S Ratio-2.4x
P/E RatioIs 0IF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IF income statement (TTM) | |
|---|---|
| Revenue | US$10.76m |
| Cost of Revenue | US$30.68m |
| Gross Profit | -US$19.92m |
| Other Expenses | US$6.62m |
| Earnings | -US$26.54m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | -185.15% |
| Net Profit Margin | -246.71% |
| Debt/Equity Ratio | 37.7% |
How did 0IF perform over the long term?
See historical performance and comparison